Ziad Hijazi1, Jonas Oldgren1, Ulrika Andersson2, Stuart J Connolly3, Michael D Ezekowitz4, Stefan H Hohnloser5, Paul A Reilly6, Agneta Siegbahn7, Salim Yusuf3, Lars Wallentin1. 1. Department of Cardiology, Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 2. Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 3. Population Health Research Institute, Hamilton, Canada. 4. Thomas Jefferson Medical College and the Heart Center, Wynnewood, Pennsylvania, USA. 5. Department of Cardiology, J. W. Goethe University, Frankfurt, Germany. 6. Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA. 7. Department of Medical Sciences, Uppsala Clinical Research Center, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Abstract
OBJECTIVES: To evaluate the prognostic importance of transient or persistent elevations of cardiac troponin-I (cTnI) and N-terminal-B-type natriuretic peptide (NT-proBNP) in atrial fibrillation (AF). METHODS: Plasma samples were obtained at randomisation and after 3 months in 2514 patients with AF in the RE-LY trial; median follow-up was 2.0 years. Patients were grouped based on levels at the two time points according to detectable cTnI levels (≥0.01 µg/L) or NT-proBNP levels above median (≥778 ng/L). These groups were related to occurrence of stroke or cardiovascular events evaluated with Cox models adjusting for established risk factors. RESULTS: The proportion of patients with detectable cTnI levels at both time points was 48.5%, at one time point 28.5% and at neither time point 21.0%. Patients with detectable cTnI at both time points had substantially higher rates of stroke compared with those with transient elevations and those with no elevation at either time point (p<0.005, effect of cTnI). Persistent elevation of either or both cardiac biomarkers at baseline and 3 months was associated with a higher risk for cardiovascular events and mortality (p<0.0001). Prognostic prediction improved most with the use of repeated measurements of both cardiac biomarkers simultaneously (p<0.05) and achieved C-statistic 0.644 for stroke compared with 0.611 for CHADS2-score. CONCLUSIONS: Persistent elevation of troponin and NT-proBNP indicates a worse prognosis than transient elevations or no elevations of either marker. Prognostication of stroke, death and thromboembolic events is improved by the use of repeated determinations of cardiac biomarkers. TRIAL REGISTRATION NUMBER: http://www.clinicaltrials.gov, NCT00262600. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
OBJECTIVES: To evaluate the prognostic importance of transient or persistent elevations of cardiac troponin-I (cTnI) and N-terminal-B-type natriuretic peptide (NT-proBNP) in atrial fibrillation (AF). METHODS: Plasma samples were obtained at randomisation and after 3 months in 2514 patients with AF in the RE-LY trial; median follow-up was 2.0 years. Patients were grouped based on levels at the two time points according to detectable cTnI levels (≥0.01 µg/L) or NT-proBNP levels above median (≥778 ng/L). These groups were related to occurrence of stroke or cardiovascular events evaluated with Cox models adjusting for established risk factors. RESULTS: The proportion of patients with detectable cTnI levels at both time points was 48.5%, at one time point 28.5% and at neither time point 21.0%. Patients with detectable cTnI at both time points had substantially higher rates of stroke compared with those with transient elevations and those with no elevation at either time point (p<0.005, effect of cTnI). Persistent elevation of either or both cardiac biomarkers at baseline and 3 months was associated with a higher risk for cardiovascular events and mortality (p<0.0001). Prognostic prediction improved most with the use of repeated measurements of both cardiac biomarkers simultaneously (p<0.05) and achieved C-statistic 0.644 for stroke compared with 0.611 for CHADS2-score. CONCLUSIONS: Persistent elevation of troponin and NT-proBNP indicates a worse prognosis than transient elevations or no elevations of either marker. Prognostication of stroke, death and thromboembolic events is improved by the use of repeated determinations of cardiac biomarkers. TRIAL REGISTRATION NUMBER: http://www.clinicaltrials.gov, NCT00262600. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel Journal: Clin Res Cardiol Date: 2018-04-27 Impact factor: 5.460
Authors: João Augusto; Miguel Borges Santos; David Roque; Daniel Faria; Joana Urzal; José Morais; Victor Gil; Carlos Morais Journal: Intern Emerg Med Date: 2017-12-23 Impact factor: 3.397
Authors: Jan Niederdöckl; Julia Oppenauer; Sebastian Schnaubelt; Filippo Cacioppo; Nina Buchtele; Alexandra-Maria Warenits; Roberta Laggner; Nikola Schütz; Magdalena S Bögl; Gerhard Ruzicka; Sophie Gupta; Martin Lutnik; Safoura Sheikh Rezaei; Michael Wolzt; Harald Herkner; Hans Domanovits; Anton N Laggner; Michael Schwameis; Ziad Hijazi Journal: Front Med (Lausanne) Date: 2022-06-27
Authors: Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah Journal: Circulation Date: 2015-07-28 Impact factor: 29.690
Authors: Kazuma Oyama; Robert P Giugliano; David D Berg; Christian T Ruff; Petr Jarolim; Minao Tang; Sabina A Murphy; Hans J Lanz; Michael A Grosso; Elliott M Antman; Eugene Braunwald; David A Morrow Journal: Eur Heart J Date: 2021-05-01 Impact factor: 29.983